Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
NCT05520099 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
Conditions Studied
Interventions
- PROCEDURE Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
Study Locations (12)
Florida
- AdventHealth Orlando — Orlando
- Memorial Health System — Pembroke Pines
- Cleveland Clinic Florida — Stuart
- University of South Florida (Tampa General Hospital) — Tampa
Arkansas
- CARTI Cancer Center — Little Rock
California
- Salinas Valley Memorial Healthcare System — Salinas
Kentucky
- University of Louisville James Graham Brown Cancer Center — Louisville
Maryland
- Meritus Center for Clinical Research — Hagerstown
New Jersey
- John Theurer Cancer Center — Hackensack
New York
- Roswell Park Comprehensive Cancer Center — Buffalo
North Carolina
- University of North Carolina at Chapel Hill — Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2027-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05520099
The ClinicalTrials.gov registry entry for NCT05520099 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elephas, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention — of which Core Needle Biopsy, Forceps Biopsy, Punch Biopsy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05520099 reports 12 study locations spanning 9 distinct geographic areas — top geographies include Florida, Arkansas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05520099 about?
NCT05520099 is a clinical study titled "Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform". The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
What is the current status of trial NCT05520099?
This trial is currently recruiting. The enrollment target is 416 participants. The study started on 2023-06-26. Estimated completion is 2027-01.
What conditions does trial NCT05520099 study?
This clinical trial studies the following conditions: Cancer, Colorectal Cancer, Bladder Cancer, Kidney Cancer, Urothelial Carcinoma Bladder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05520099?
The interventions under investigation include: Core Needle Biopsy, Forceps Biopsy, Punch Biopsy (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05520099?
This trial is sponsored by Elephas, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05520099 being conducted?
This trial has 12 study locations across Arkansas, California, Florida, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.